MEDP:NGS-Medpace Holdings Inc. (USD)

EQUITY | Diagnostics & Research | Nasdaq Global Select

Last Closing

USD 392.57

Change

0.00 (0.00)%

Market Cap

USD 1.47B

Volume

0.13M

Analyst Target

USD 118.40
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Medpace Holdings Inc is a clinical contract research organisation. It is engaged in providing scientifically-driven clinical research-based drug and medical device development services to the biotechnology, pharmaceutical and medical device industries.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-05 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

N/A

USD 42.66B
ICLR ICON PLC

N/A

USD 26.52B
ILMN Illumina Inc

N/A

USD 16.96B
NTRA Natera Inc

N/A

USD 13.45B
EXAS EXACT Sciences Corporation

N/A

USD 9.20B
RDNT RadNet Inc

N/A

USD 4.32B
SHC Sotera Health Co

N/A

USD 3.13B
GH Guardant Health Inc

N/A

USD 3.12B
OLK Olink Holding AB ADR

N/A

USD 2.98B
NEOG Neogen Corporation

N/A

USD 2.87B

ETFs Containing MEDP

S6EW:SW Ossiam STOXX® Europe 600.. 4.65 % 0.00 %

N/A

USD 0.12B
PTH Invesco DWA Healthcare Mo.. 4.50 % 0.60 %

N/A

USD 0.14B
INFR ClearBridge Sustainable I.. 3.76 % 0.47 %

N/A

USD 8.31M
AMID Argent Mid Cap ETF 3.54 % 0.00 %

N/A

USD 0.06B
XCLN:CA iShares Global Clean Ener.. 3.46 % 0.00 %

N/A

CAD 8.43M
INRG:SW iShares Global Clean Ener.. 3.45 % 0.00 %

N/A

USD 3.24B
JSMD Janus Henderson Small/Mid.. 2.94 % 0.50 %

N/A

USD 0.36B
FXH First Trust Health Care A.. 2.10 % 0.63 %

N/A

USD 1.27B
RFG Invesco S&P MidCap 400® .. 1.91 % 0.35 %

N/A

USD 0.35B
HEAL:SW iShares Healthcare Innova.. 1.77 % 0.00 %

N/A

N/A
2B78:F iShares Healthcare Innova.. 1.72 % 0.00 %

N/A

N/A
QSML:AU VanEck MSCI International.. 1.26 % 0.00 %

N/A

USD 0.57B
FHH:CA First Trust AlphaDEX US H.. 0.00 % 0.77 %

N/A

CAD 0.01B
XMHQ Invesco S&P MidCap Qualit.. 0.00 % 0.25 %

N/A

USD 5.17B
DRDR:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

USD 1.06B
HEAL:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

USD 1.06B
INRG:LSE iShares Global Clean Ener.. 0.00 % 0.00 %

N/A

USD 3.26B
L6EW:LSE Ossiam Stoxx Europe 600 E.. 0.00 % 0.00 %

N/A

USD 0.12B
LCPE:LSE Ossiam Shiller Barclays C.. 0.00 % 0.00 %

N/A

USD 0.17B
S6EW:LSE Ossiam Stoxx Europe 600 E.. 0.00 % 0.00 %

N/A

USD 0.12B
JELS:LSE 0.00 % 0.00 %

N/A

N/A
UTIL:LSE SPDR® MSCI Europe Utilit.. 0.00 % 0.00 %

N/A

USD 0.11B
S6EW:PA Ossiam Stoxx Europe 600 E.. 0.00 % 0.00 %

N/A

USD 0.12B
STU:PA SPDR® MSCI Europe Utilit.. 0.00 % 0.00 %

N/A

USD 0.11B
IQQH:F iShares Global Clean Ener.. 0.00 % 0.00 %

N/A

USD 3.24B
OSX6:F Ossiam Lux - Ossiam Stoxx.. 0.00 % 0.00 %

N/A

USD 0.12B
SPYU:F SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

N/A

USD 0.11B
2B78:XETRA iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

USD 1.14B
DXSH:XETRA Xtrackers - Stoxx Europe .. 0.00 % 0.00 %

N/A

USD 0.03B
IQQH:XETRA iShares Global Clean Ener.. 0.00 % 0.00 %

N/A

USD 3.34B
OSX6:XETRA Ossiam Stoxx Europe 600 E.. 0.00 % 0.00 %

N/A

USD 0.16B
SPYU:XETRA SPDR® MSCI Europe Utilit.. 0.00 % 0.00 %

N/A

USD 0.16B
ZCLN:CA BMO Clean Energy Index ET.. 0.00 % 0.00 %

N/A

CAD 0.07B
IBBJ 0.00 % 0.00 %

N/A

N/A
FHH-F:CA First Trust AlphaDEX U.S... 0.00 % 0.00 %

N/A

CAD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 28.07% 88% B+ 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 28.07% 88% B+ 86% B+
Trailing 12 Months  
Capital Gain 89.84% 95% A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 89.84% 95% A 93% A
Trailing 5 Years  
Capital Gain 585.83% 100% F 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 585.83% 100% F 97% N/A
Average Annual (5 Year Horizon)  
Capital Gain 44.53% 82% B 89% A-
Dividend Return 44.53% 82% B 89% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 38.97% 65% D 46% F
Risk Adjusted Return 114.27% 100% F 99% N/A
Market Capitalization 1.47B 94% A 94% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 128.40 39% 24%
Price/Book Ratio 21.90 6% 5%
Price / Cash Flow Ratio 28.31 12% 9%
Price/Free Cash Flow Ratio 33.42 6% 7%
Management Effectiveness  
Return on Equity 61.35% 98% 98%
Return on Invested Capital 57.06% 100% 96%
Return on Assets 13.89% 98% 98%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.